Top Diversified Bank Stocks To Buy Right Now

Banks and financial sector firms are still held in low repute by public opinion in many countries. Taxpayers and retail investors along with average citizens still distrust stock markets, high frequency trading and resent their banks, brokers and insurance firms due to their heavy losses and bailouts since 2008's crises.

Now, as financial firms seek to restore confidence and trust, a new series of indictments are brought by Jeremy Leggett in The Energy of Nations: Risk Blindness and the Road to Renaissance. Leggett is a former oil executive, geologist, founder of the successful Solarcentury company and its charity SolarAid, and chair of the influential financial think tank Carbon Tracker. Leggett, also a celebrity in his native Britain, contributes to the Financial Times, The Guardian, and is a Fellow at Oxford University's Environmental Change Institute.

Leggett, as an insider, sat in many British parliamentary meetings, the World Economic Forum, as well as multiple meetings of the International Chamber of Commerce, the International Energy Agency (IEA), the Bank of England and other high-level, closed-door financial meetings on the 2008 crises and continuing aftermath. So Leggett's evidence for his indictments of banks, institutional investors, hedge funds, private equity and VCs are documented in detail - many from his firsthand observations. His further indictments beyond the risk-taking that helped cause the 2008 financial meltdown are against these same short-term financial players together with their long-time clientele of incumbent energy sector companies (utilities, coal, nuclear, petroleum, gas, pipelines, transmission) and compliant bureaucrats and politicians.

Top 5 Warren Buffett Companies To Buy For 2015: Dolan Co (DM)

The Dolan Company, incorporated in March 2003, is a provider of necessary professional services and business information to legal, financial and real estate sectors in the United States. The Company operates through two operating divisions: its Professional Services Division and its Business Information Division. Its Professional Services Division consists of two segments: mortgage default processing services and litigation support services. Its Business Information Division produces legal publications, business journals, court and commercial media, other online information products and services, and operates Websites and produces events for targeted professional audiences in 21 geographic markets across the United States. Its information is delivered through a variety of methods, including approximately 60 print publications and 80 Websites. The Company also operates specialized information services covering legislative and regulatory activities and providing transcription, media monitoring and translation services. On July 25, 2011, it acquired substantially all of the assets of ACT Litigation Services, Inc. (ACT). In July 2013, the Company sold the assets of its NDeX South business to the law firm affiliates of that business.

Professional Services

The Company�� Professional Services Division consists of two operating segments: mortgage default processing services and litigation support services. Its mortgage default processing services segment consists of the operations of NDeX. Its litigation support services segment consists of the operations of DiscoverReady, its discovery management and document review services business, and Counsel Press, its appellate services business. The Company provides these support services to the legal profession. In addition, NDeX also provides its services directly to mortgage lenders and loan servicers on California foreclosure files. One of the litigation support services it provides is discovery management and document review services, ! including certain technology services related to processing and hosting the data. Discovery is the process by which parties use the legal system to obtain relevant information, primarily in litigation, regulatory, and governmental investigation matters. Some United States companies with in-house legal departments choose to perform or manage some portions of the discovery process in-house, rather than outsourcing them.

The Company provides appellate services to lawyers in connection with both state and federal appeals. It performs more state appellate work, as state appellate case volume generally is larger than federal case volume. There are typically about 300,000 state appeals filed each year, compared to approximately 58,000 federal appeals filed per year, according to information available to the Company from the Administrative Office of the United States Courts and the National Center for State Courts. NDeX also provides real estate title services to the Barrett Law Firm and provides loan modification and loss mitigation support on mortgage default files to its customers. During the year ended December 31, 2011, it received approximately 317,200 mortgage default case files for processing from its customers.

In 2011, its mortgage default processing services segment accounted for 46% of its total revenues and 63% of its Professional Services Division�� total revenues. The Company�� litigation support services professionals at Counsel Press provide clients with consulting services, including procedural and technical advice and support with respect to the United States state and federal appellate processes. During 2011, its litigation support services segment accounted for 27% of its total revenues and 37% of its Professional Services Division�� total revenues. In addition to its appellate services, Counsel Press provides additional tracking and professional services to its clients.

Business Information

The Company provides business informatio! n product! s to companies and professionals in the legal, financial, real estate and governmental affairs sectors primarily through print and online business journals and court and commercial newspapers, as well as other electronic media offerings. Its business journals generally rely on display and classified advertising as a significant source of revenue and provide content that is relevant to the business communities they target. Its court and commercial newspapers generally rely on public notices as their primary source of revenue and offer information to the legal communities they target. All of its business journals and court and commercial newspapers also generate circulation revenue to supplement their advertising and public notice revenue base. There were more than 230 local business journals and more than 350 court and commercial newspapers nationwide, which generated approximately $2 billion in revenues in 2011.

The Company sells packaged print and online advertising products to advertisers that desire to reach readers through different media. Dolan Media Newswires, its Internet-based, subscription newswire, is available at www.dolanmedianewswires.com for news professionals and represents the work of its journalists and contributors. It also operates online, subscription-based legislative information services that are used by lobbyists, associations, corporations, unions, government affairs professionals, state agencies and the media in Arizona, Minnesota and Oklahoma. Through DataStream, it offers customized access to legislative databases, which provide state and federal legislative and regulatory information. Through Federal News, the Company offers transcription services.

The Company provides commercial printing services and sells database information through royalty or licensing fee arrangements. During2011, its subscription-based and other revenues accounted for 8% of its total revenues and 28% of its Business Information Division�� total revenues. The Company prints se! ven of it! s business information publications at one of its three printing facilities located in Baltimore, Minneapolis and Oklahoma City.

Advisors' Opinion:

• [By Sally Jones]

  Dolan Co. (DM) ��Market Cap $81.8 Million

  Dolan Co. is down 42% over 12 months. The company has a market cap of $81.8 million; its trades at around $2.65 with a P/B ratio of 1.10.

• [By Roberto Pedone]

  Another under-$10 stock that looks poised for a sharp move higher is Dolan (DM), a provider of necessary business information and professional services to the legal, financial and real estate sectors in the U.S. This stock has been hammered by the sellers so far in 2013, with shares off huge by 80%.

  If you take a look at the chart for Dolan Company, you'll notice that this stock has been downtrending badly over the last two months, with shares plunging lower from its high of $3 a share to its recent low of 66 cents per share. During that downtrend, shares of DM have been consistently making lower highs and lower lows, which is bearish technical price action. That move has now pushed shares of DM into oversold territory, since its current relative strength index reading is 20. Oversold can always get more oversold, but it's also an area where a stock can make a powerful bounce higher from.

  Market players should now look for long-biased trades in DM if it manages to break out above Thursday's high of 77 cents per share and then above some more near-term overhead resistance at 80 cents per share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 321,823 shares. If that breakout hits soon, then DM will set up for a possible powerful bounce higher that could easily take this stock back above $1 to $1.20 a share.

  Traders can look to buy DM off weakness to anticipate that breakout and simply use a stop that sits right around some key near-term support levels at 71 cents to 66 cents per share. One can also buy DM off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Holly LaFon]

  After years of strong performance, emerging markets have recently underperformed developed markets (DM), as shown in Exhibit 1.

  [ Enlarge Image ]

• [By Lisa Levin]

  The Dolan Company (NYSE: DM) shares fell 27.23% to reach a new 52-week low of $0.50 after the company received a continued listing standards notice from the NYSE and appointed Kevin Nystrom as Chief Restructuring Officer.

Top Diversified Bank Stocks To Buy Right Now: Oramed Pharmaceuticals Inc (ORMP)

Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.

The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.

Advisors' Opinion:

• [By Lisa Levin]

  Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.

• [By Ben Levisohn]

  Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.

  BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.

• [By Lisa Levin]

  Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.

Top Diversified Bank Stocks To Buy Right Now: Apple Inc.(AAPL)

Apple Inc., together with subsidiaries, designs, manufactures, and markets personal computers, mobile communication and media devices, and portable digital music players, as well as sells related software, services, peripherals, networking solutions, and third-party digital content and applications worldwide. The company sells its products worldwide through its online stores, retail stores, direct sales force, third-party wholesalers, resellers, and value-added resellers. In addition, it sells third-party Mac, iPhone, iPad, and iPod compatible products, including application software, printers, storage devices, speakers, headphones, and other accessories and peripherals through its online and retail stores; and digital content and applications through the iTunes Store. The company sells its products to consumer, small and mid-sized business, education, enterprise, government, and creative markets. As of September 25, 2010, it had 317 retail stores, including 233 stores in the United States and 84 stores internationally. The company, formerly known as Apple Computer, Inc., was founded in 1976 and is headquartered in Cupertino, California.

Advisors' Opinion:

• [By Alex Planes]

  Big labor loses big
  On April 14, 1992, the same day its future Dow compatriot beat back Apple's (NASDAQ: AAPL  ) legal assault, Caterpillar (NYSE: CAT  ) gained a critical victory against the United Automobile Workers union. More than 12,000 workers stopped picketing Caterpillar's Peoria, Ill., plant, despite having called the company's offer "a mean-spirited proposal" up until the end of the strike. The five-month action was the first in a series of major union efforts against the heavy-equipment manufacturer, and the UAW's capitulation in the spring of 1992 set the tone for the strikes yet to come.

• [By Rich Smith]

  Over in Russia, market-leading cell phone provider Mobile TeleSystems (NYSE: MBT  ) has just confirmed that, as of 2012, it no longer sells Apple's (NASDAQ: AAPL  ) new iPhone models to its customers directly. The company does still stock, and sell, some older iPhone models. But for iPhone5 and on up, MTS now answers phone calls from Apple with a Spasibo, ne nada. ("Thanks, but no thanks.")

• [By MONEYMORNING.COM]

  Apple Inc. (Nasdaq: AAPL) is not a rash and foolish company, and neither is its CEO, Tim Cook.

  So the general condemnation in the media of the possible purchase of Santa Monica, Calif.-based Beats Electronics for $3.2 billion by the Cupertino, Calif.-based tech giant seems a bit premature.

• [By Rick Munarriz]

  Apple (NASDAQ: AAPL  ) hit a fresh 52-week low this week, and it's clear that there's a confidence crisis as we head into Tuesday's quarterly report.

Top Diversified Bank Stocks To Buy Right Now: Optimer Pharmaceuticals Inc.(OPTR)

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing hospital specialty products worldwide. It develops products that treat gastrointestinal infections and related diseases. The company provides two late-stage anti-infective product candidates, including Fidaxomicin, a narrow spectrum antibiotic for the treatment of Clostridium difficile-infection, which completed two Phase 3 trials; and Pruvel, a prodrug in the fluoroquinolone class of antibiotics, has completed two Phase 3 trials for the treatment of infectious diarrhea, including traveler?s diarrhea. It also develops product candidates using its proprietary technology Optimer One-Pot Synthesis, a computer-aided technology that enables the rapid synthesis of various proprietary molecules. In addition, the company?s other pipeline product candidates consist of CEM-101 (OP-1068), a macrolide and ketolide antibiotic, which is in Phase 2 trials for the treatment of upper and lower respiratory tract infections; and OPT-822/821, a novel carbohydrate-based cancer immunotherapy, is in Phase 2/3 trials for the treatment of metastatic breast cancer. It has collaborative agreements with Astellas Pharma Europe Ltd.; Par Pharmaceuticals, Inc.; Nippon Shinyaku, Co., Ltd.; Cempra Pharmaceuticals, Inc.; Memorial Sloan-Kettering Cancer Center; and The Scripps Research Institute. Optimer Pharmaceuticals, Inc. was founded in 1998 and is based in San Diego, California.

Advisors' Opinion:

• [By Keith Speights]

  "Bidness" is good (part 2)
  Obagi isn't the only company for which "bidness" is good. Antibiotic maker�Optimer Pharmaceuticals (NASDAQ: OPTR  ) shares soared 22% this week on talk of interest by multiple potential buyers.